C. Carter

An Analysis of Lymphocyte Phenotype After Steroid Avoidance With Either Alemtuzumab or Basiliximab Induction in Renal Transplantation

A. Cherukuri, A. Salama, M. Hernandez-Fuentes, 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Risk of early renal allograft failure is increased for patients with antiphospholipid antibodies

J. Mcintyre, D. Wagenknecht, C. Carter, 2000, Transplant international : official journal of the European Society for Organ Transplantation.

Stented Lich-Gregoir ureteroneocystostomy: case series report and cost-effectiveness analysis.

R. Mangus, C. Carter, B. Haag, 2004, Transplantation proceedings.

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients.

C. V. van Buren, B. Kahan, S. Katz, 1999, Transplantation.

Antiphospholipid antibodies are a risk factor for early renal allograft failure: isolation of antiphospholipid antibodies from a thrombosed renal allograft.

D. Wagenknecht, C. Carter, R. Torry, 1999, Transplantation proceedings.

MULTIPLE-DOSE PHARMACOKINETICS OF THE IMMUNOSUPPRESSANT SDZ RAD IN STABLE RENAL TRANSPLANT PATIENTS

M. Wilkie, B. Kahan, R. Wong, 1998 .

The endothelial heparan sulfate-antithrombin III natural anticoagulant pathway in normal and transplanted human kidneys.

W. Faulk, C. Labarrere, C. Carter, 1992, Transplantation.

Tubular antithrombin at transplantation determines subsequent renal allograft function.

D. Nelson, W. Faulk, C. Labarrere, 1998, Transplantation.